You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康希諾生物-B漲逾8%創新高 今年迄今已累漲逾140%
格隆匯 04-02 11:53
格隆匯4月2日丨康希諾生物-B(6185.HK)今日盤中高見142.6港元,再創歷史新高。現報142港元,漲8.31%,暫成交9810萬港元,最新總市值316億港元。該股去年累漲93.28%,今年迄今已累漲逾140%。公司曾於3月18日公佈,由公司與軍事科學院軍事醫學研究院生物工程研究所聯合開發的重組新型冠狀病毒疫苗(腺病毒載體)(Ad5-nCoV)已經通過了臨牀研究註冊審評,獲批進入臨牀試驗。大摩發研報將其目標價由68港元大幅提升至102港元,予“增持”評級,以反映疫苗銷售提升的影響,並密切關注Ad5-nCoV的開發進程,但現階段認為成功率僅為20%左右。此外,公司近日發佈2019年度業績稱,期內公司並無產生任何收入;研發開支同比增加33.5%至2019年度的1.517億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account